[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Tanaka N, Kato H, Inose T, Kimura H, Faried A, Sohda M, Nakajima M, Fukai Y, Miyazaki T, Masuda N, Fukuchi M, Kuwano H: Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma. Br J Cancer; 2008 Nov 4;99(9):1468-75
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma.
  • Hypoxic conditions are known to be associated with resistance to chemotherapy and radiotherapy, and with poor cancer prognosis.
  • We examined CA9 expression in surgical specimens from oesophageal squamous cell carcinoma (ESCC) patients (n=127) using immunohistochemistry and real-time RT-PCR.
  • We also examined CA9 expression and cell proliferation in ESCC cell lines (TE-2, TE-8 and TE-15) and an immortalised human oesophageal cell line (CHEK-1) using real-time RT-PCR, Western blotting, ELISA and MTT assay.
  • Immunohistochemistry, high expression of CA9 was found in 63 of the 127 primary tumour specimens and was correlated with poor outcome (P=0.0003) and more aggressive/less favourable clinicopathological parameters (tumour size (P=0.0235), tumour depth (P<0.0001), regional lymph node metastasis (P=0.0031), distant lymph node metastasis (P=0.0077), stage (P<0.0001) and blood vessel invasion (P=0.006)).
  • CA9 is correlated with poor prognosis and malignant phenotype in patients with ESCC, and was upregulated by hypoxia.
  • It is suggested that control of CA9 expression might improve the effectiveness of chemotherapy and radiotherapy in ESCC.
  • [MeSH-major] Antigens, Neoplasm / analysis. Carbonic Anhydrases / analysis. Carcinoma, Squamous Cell / enzymology. Esophageal Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Biomarkers. Cell Hypoxia. Cell Line, Tumor. Cell Proliferation. Female. Humans. Male. Middle Aged. Prognosis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Feb 1;21(3):473-82 [12560438.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6C):3977-84 [12553021.001]
  • [Cites] Radiother Oncol. 2003 Apr;67(1):35-44 [12758238.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4641-52 [14581333.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4592-6 [14673047.001]
  • [Cites] J Pathol. 2004 May;203(1):551-8 [15095478.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6160-5 [15342400.001]
  • [Cites] J Enzyme Inhib Med Chem. 2004 Jun;19(3):199-229 [15499993.001]
  • [Cites] Physiol Rev. 1967 Oct;47(4):595-781 [4964060.001]
  • [Cites] Bioessays. 1989 Jun;10(6):186-92 [2500929.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;119(8):441-9 [8509434.001]
  • [Cites] Oncogene. 1994 Oct;9(10):2877-88 [8084592.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):941-3 [8640781.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4509-15 [8813149.001]
  • [Cites] Hum Pathol. 1997 Jun;28(6):740-4 [9191010.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7608-13 [9636197.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12596-601 [9770531.001]
  • [Cites] FEBS Lett. 2004 Nov 19;577(3):439-45 [15556624.001]
  • [Cites] Oncology. 2005;69(1):71-80 [16103736.001]
  • [Cites] J Clin Oncol. 2005 Dec 10;23(35):8932-41 [16219933.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):473-7 [16428489.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):334-40 [16495697.001]
  • [Cites] Lung Cancer. 2006 Apr;52(1):59-66 [16513206.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6421-31 [17085655.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):68-75 [17200340.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):329-33 [17233814.001]
  • [Cites] Radiother Oncol. 1999 Nov;53(2):113-7 [10665787.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2220-4 [10688890.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7075-83 [11156414.001]
  • [Cites] Ann Surg. 2001 Jul;234(1):25-32 [11420480.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3660-8 [11504747.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6394-9 [11522632.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7992-8 [11691824.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3399-403 [11705854.001]
  • [Cites] Cancer Lett. 2002 Mar 8;177(1):21-8 [11809527.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):802-11 [12576453.001]
  • (PMID = 18841153.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers; 0 / RNA, Messenger; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ PMC2579701
  •  go-up   go-down


2. Amjad AI, Pal I: De novo primary squamous cell carcinoma of the ovary: a case of a rare malignancy with an aggressive clinical course. J Pak Med Assoc; 2008 May;58(5):272-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De novo primary squamous cell carcinoma of the ovary: a case of a rare malignancy with an aggressive clinical course.
  • Ovarian squamous cell carcinoma is a rare malignancy and the occurrence is attributable to malignant transformation of an existing ovarian dermoid cyst.
  • The de novo occurrence of squamous cell carcinoma of the ovary, in the absence of an antecedent ovarian dermoid, is extremely rare.
  • Abdominal CT was suggestive of a malignant neoplastic process.
  • Laparotomy confirmed a malignant tumour with involvement of the right adnexa and extension into the omentum and bowel.
  • Histopathology demonstrated squamous cell carcinoma arising from the right ovary with no co-existing ovarian dermoid.
  • The postoperative period was significant for disease progression despite adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Ovarian Neoplasms / diagnosis. Ovariectomy / methods
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Colectomy / methods. Diagnosis, Differential. Disease Progression. Elective Surgical Procedures / methods. Female. Follow-Up Studies. Humans. Ileostomy / methods. Laparotomy. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18655408.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Hille A, Grüger S, Christiansen H, Wolff HA, Volkmer B, Lehmann J, Dörr W, Rave-Fränk M: Effect of tumour-cell-derived or recombinant keratinocyte growth factor (KGF) on proliferation and radioresponse of human epithelial tumour cells (HNSCC) and normal keratinocytes in vitro. Radiat Environ Biophys; 2010 May;49(2):261-70
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of tumour-cell-derived or recombinant keratinocyte growth factor (KGF) on proliferation and radioresponse of human epithelial tumour cells (HNSCC) and normal keratinocytes in vitro.
  • Purpose of this work was to test the effect of tumour-cell-derived keratinocyte growth factor (KGF) or recombinant KGF (palifermin) on cell proliferation and radiation response of human HNSCC cells and normal keratinocytes in vitro.
  • Four tumour cell cultures derived from head and neck squamous cell carcinomas, primary keratinocytes, and immortalized keratinocytes were analysed.
  • KGF expression was observed in primary and immortalized keratinocytes, fibroblasts, and in tumour cells, while significant KGF receptor expression was only found in keratinocytes.
  • Recombinant KGF as well as tumour-cell-derived KGF caused a significant growth stimulation and radioprotection in keratinocytes, which was abolished by a neutralizing anti-KGF antibody.
  • This indicates that tumour-cell-derived KGF is biologically active.
  • In the tumour cell lines, no significant growth stimulation was induced by recombinant KGF, and the neutralizing antibody did not influence tumour cell growth or radiation response.
  • Our results indicate that the normal, paracrine KGF regulatory mechanisms, which are based on KGF receptor expression, are lost in malignant cells, with the consequence of irresponsiveness of the tumour cells to exogenous KGF.
  • In face of the amelioration of the radiation response of normal epithelia, demonstrated in various clinical and various preclinical animal studies, recombinant KGF represents a candidate for the selective protection of normal epithelia during radio(chemo) therapy of squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Fibroblast Growth Factor 7 / pharmacology. Head and Neck Neoplasms / pathology. Keratinocytes / drug effects. Keratinocytes / radiation effects. Recombinant Proteins / pharmacology
  • [MeSH-minor] Antibodies / immunology. Antibodies / pharmacology. Cell Line, Tumor. Cell Proliferation / drug effects. Culture Media, Conditioned / metabolism. Enzyme-Linked Immunosorbent Assay. Fibroblasts / metabolism. Humans. Polymerase Chain Reaction. Receptor, Fibroblast Growth Factor, Type 2 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prostate. 1999 Dec 1;41(4):233-42 [10544296.001]
  • [Cites] J Pathol. 2004 Sep;204(1):110-8 [15307144.001]
  • [Cites] Mol Cell Endocrinol. 2000 Sep 25;167(1-2):77-87 [11000522.001]
  • [Cites] Int J Radiat Biol. 2001 Mar;77(3):341-7 [11258848.001]
  • [Cites] Am J Clin Oncol. 2001 Oct;24(5):491-5 [11586102.001]
  • [Cites] Radiat Res. 2001 Dec;156(6):761-6 [11741500.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):911-7 [11958883.001]
  • [Cites] Cell Prolif. 2002 Aug;35 Suppl 1:86-92 [12139711.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):245-51 [12182998.001]
  • [Cites] Int J Radiat Biol. 2003 Feb;79(2):119-28 [12569015.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1452-8 [12697866.001]
  • [Cites] Int J Radiat Biol. 2003 Jul;79(7):531-7 [14530162.001]
  • [Cites] J Cell Biol. 1988 Mar;106(3):761-71 [2450098.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Oct 4;215(1):309-15 [7575607.001]
  • [Cites] Br J Cancer. 1997;75(11):1567-74 [9184170.001]
  • [Cites] J Oral Pathol Med. 1997 Aug;26(7):327-33 [9250933.001]
  • [Cites] Radiat Res. 1997 Sep;148(3):248-53 [9291356.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):177-87 [9422575.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):933-9 [9500453.001]
  • [Cites] Toxicol Pathol. 1999 Jan-Feb;27(1):64-71 [10367676.001]
  • [Cites] Int J Radiat Biol. 1999 May;75(5):609-20 [10374943.001]
  • [Cites] N Engl J Med. 2004 Dec 16;351(25):2590-8 [15602019.001]
  • [Cites] Radiother Oncol. 2005 Apr;75(1):99-105 [15878107.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):881-7 [15936573.001]
  • [Cites] Int J Radiat Biol. 2005 Aug;81(8):557-65 [16298937.001]
  • [Cites] Expert Opin Emerg Drugs. 2006 May;11(2):353-73 [16634706.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 21;98(12):812-24 [16788155.001]
  • [Cites] Strahlenther Onkol. 2006 Oct;182(10):567-75 [17013569.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 1;350(4):825-33 [17049492.001]
  • [Cites] Cancer. 2007 Mar 1;109(5):820-31 [17236223.001]
  • [Cites] Radiat Environ Biophys. 2007 Mar;46(1):13-9 [17103218.001]
  • [Cites] Int J Oncol. 2007 Oct;31(4):721-8 [17786302.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):528-33 [17869665.001]
  • [Cites] Traffic. 2007 Dec;8(12):1854-72 [17944804.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2489-96 [18487568.001]
  • [Cites] Stem Cells. 2008 Oct;26(10):2595-601 [18669914.001]
  • [Cites] J Oral Pathol Med. 2009 May;38(5):476-80 [19434818.001]
  • [Cites] Pathol Int. 2000 May;50(5):363-72 [10849325.001]
  • (PMID = 20213138.001).
  • [ISSN] 1432-2099
  • [Journal-full-title] Radiation and environmental biophysics
  • [ISO-abbreviation] Radiat Environ Biophys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies; 0 / Culture Media, Conditioned; 0 / Recombinant Proteins; 126469-10-1 / Fibroblast Growth Factor 7; EC 2.7.1.- / keratinocyte growth factor receptor; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 2
  • [Other-IDs] NLM/ PMC2855434
  •  go-up   go-down


Advertisement
4. Marur S, D'Souza G, Westra WH, Forastiere AA: HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol; 2010 Aug;11(8):781-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A rise in incidence of oropharyngeal squamous cell cancer--specifically of the lingual and palatine tonsils--in white men younger than age 50 years who have no history of alcohol or tobacco use has been recorded over the past decade.
  • This malignant disease is associated with human papillomavirus (HPV) 16 infection.
  • The best method to detect virus in tumour is controversial, and both in-situ hybridisation and PCR are commonly used; P16 immunohistochemistry could serve as a potential surrogate marker.
  • HPV-positive oropharyngeal cancer seems to be more responsive to chemotherapy and radiation than HPV-negative disease.
  • What is the potential of HPV vaccines for primary prevention?
  • Could an accurate method to detect HPV in tumour be developed?
  • Which treatment strategies reduce toxic effects without compromising survival?
  • Our aim with this review is to highlight current understanding of the epidemiology, biology, detection, and management of HPV-related oropharyngeal head and neck squamous cell carcinoma, and to describe unresolved issues.
  • [MeSH-major] Carcinoma, Squamous Cell / virology. Human papillomavirus 16. Oropharyngeal Neoplasms / virology. Papillomavirus Infections / complications. Tumor Virus Infections / complications
  • [MeSH-minor] Biomarkers, Tumor. Female. Humans. In Situ Hybridization. Incidence. Male. Middle Aged. Polymerase Chain Reaction. Risk Factors. Sex Distribution. Survival Rate

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Oral Oncol. 2003 Jan;39(1):31-6 [12457719.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 [15734974.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2875-84 [11753961.001]
  • [Cites] Radiother Oncol. 1996 Sep;40(3):197-223 [8940748.001]
  • [Cites] Acta Otolaryngol. 2005 Dec;125(12):1337-44 [16303684.001]
  • [Cites] Cancer. 2005 May 1;103(9):1843-9 [15772957.001]
  • [Cites] Am J Surg Pathol. 2008 Jul;32(7):1044-50 [18496144.001]
  • [Cites] Arch Med Res. 2008 Feb;39(2):189-97 [18164962.001]
  • [Cites] Int J Cancer. 2005 Nov 20;117(4):605-10 [15929076.001]
  • [Cites] Int J Cancer. 2004 Feb 20;108(5):766-72 [14696105.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1186-91 [17317828.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2087-96 [18708401.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5694-9 [16115905.001]
  • [Cites] Ann Oncol. 2008 Oct;19(10):1681-90 [18558666.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):825-32 [17131312.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] J Infect Dis. 2009 May 1;199(9):1263-9 [19320589.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):449-55 [15026470.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Jan;91(1):62-9 [11174573.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3138-46 [18474879.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):366-9 [18223210.001]
  • [Cites] Int J Cancer. 1996 Nov 15;68(4):506-13 [8945623.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1989 May;115(5):621-5 [2539843.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):143-50 [17354235.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):93-8 [12504040.001]
  • [Cites] Mol Oncol. 2007 Dec;1(3):350-5 [19383307.001]
  • [Cites] Annu Rev Pathol. 2009;4:49-70 [18729723.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):376-86 [18223558.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6469-75 [14695150.001]
  • [Cites] J Natl Cancer Inst. 2007 Dec 5;99(23):1801-10 [18042931.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] Oral Oncol. 2008 Oct;44(10):915-9 [18329326.001]
  • [Cites] Clin Cancer Res. 2009 Mar 1;15(5):1645-54 [19240170.001]
  • [Cites] J Cell Biochem. 2000 May;78(2):334-49 [10842327.001]
  • [Cites] Anticancer Res. 2008 Jul-Aug;28(4B):2077-80 [18751378.001]
  • [Cites] Head Neck. 2009 Nov;31(11):1393-422 [19787782.001]
  • [Cites] Cancer. 2008 Apr 25;114(2):118-23 [18300234.001]
  • [Cites] Acta Otolaryngol. 2007 Sep;127(9):988-92 [17712680.001]
  • [Cites] Bull Cancer. 2000 Aug;87 Spec No:48-53 [11082723.001]
  • [Cites] Int J Cancer. 2009 Jul 15;125(2):362-6 [19330833.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4171-5 [11106228.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):69-76 [14657228.001]
  • [Cites] Int J Cancer. 2006 Dec 1;119(11):2620-3 [16991119.001]
  • [Cites] Laryngoscope. 1999 Oct;109(10):1544-51 [10522920.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1626-36 [9811312.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2901-9 [18980273.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6C):4375-83 [16334111.001]
  • [Cites] Int J Cancer. 2008 Jun 15;122(12):2656-64 [18360824.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):805-13 [11550151.001]
  • [Cites] Oral Oncol. 2009 Sep;45(9):e85-9 [19457708.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):612-9 [18235120.001]
  • [Cites] Laryngoscope. 1998 Jul;108(7):1098-103 [9665264.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3128-37 [18474878.001]
  • [Cites] J Med Virol. 2009 May;81(5):878-87 [19319944.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2465-72 [17680565.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):5-13 [9426048.001]
  • [Cites] Oral Oncol. 2006 Jul;42(6):586-92 [16469526.001]
  • [Cites] Head Neck. 2008 Jul;30(7):898-903 [18383529.001]
  • [Cites] J Infect Dis. 2004 Feb 15;189(4):686-98 [14767823.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):7143-50 [18981014.001]
  • [Cites] Oncogene. 2002 Feb 28;21(10):1510-7 [11896579.001]
  • [Cites] J Huazhong Univ Sci Technolog Med Sci. 2008 Apr;28(2):197-9 [18480997.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4170-6 [16943533.001]
  • [Cites] Oral Oncol. 2008 Mar;44(3):242-50 [17467327.001]
  • [Cites] Pediatr Infect Dis J. 2007 Sep;26(9):836-40 [17721381.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):407-20 [18334711.001]
  • [Cites] Strahlenther Onkol. 2000 Jun;176(6):278-85 [10897255.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):709-20 [10793107.001]
  • (PMID = 20451455.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / R01 DE021395
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 75
  •  go-up   go-down


5. Sculier JP, Lafitte JJ, Berghmans T, Van Houtte P, Lecomte J, Thiriaux J, Efremidis A, Koumakis G, Giner V, Richez M, Corhay JL, Wackenier P, Lothaire P, Paesmans M, Mommen P, Ninane V, European Lung Cancer Working Party: A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. Ann Oncol; 2004 Mar;15(3):399-409
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer.
  • PURPOSE: The aim of this study was to determine the role of chemotherapy dose intensity in patients with initially unresectable non-metastatic non-small-cell lung cancer (NSCLC), with survival as primary end point, by testing two different regimens as induction chemotherapy followed by thoracic irradiation.
  • PATIENTS AND METHODS: Patients had pathologically proven NSCLC, an initially unresectable non-metastatic tumour without homolateral malignant pleural effusion, no prior history of malignancy and had received no prior therapy.
  • Treatment was randomised for chemotherapy between three courses of MIP (mitomycin C 6 mg/m2; ifosfamide 3 g/m2; cisplatin 50 mg/m2) or SuperMIP (mitomycin C 6 mg/m2; ifosfamide 4.5 g/m2; cisplatin 60 mg/m2, carboplatine 200 mg/m2), followed by chest irradiation (60 Gy; five times per week, for 6 weeks).
  • If the tumour became resectable after chemotherapy, surgery was performed, followed by mediastinal irradiation.
  • After induction chemotherapy, surgery was performed in 54 (15%) patients (27 per arm) and chest irradiation in 203 (57%) patients (102 in the MIP arm and 101 in the SuperMIP).
  • In terms of survival, there was no statistically significant difference between the two study arms (P=0.16), with median survival times of, for MIP and SuperMIP, respectively, 12.5 (95% CI 10.1-14.9) and 11.2 (95% CI 9.7-12.8) months.
  • Haematological toxicity and dosage reductions were higher with SuperMIP, which was nevertheless associated with a significantly increased absolute dose intensity.
  • CONCLUSIONS: High dose-intensity induction chemotherapy does not improve survival in initially unresectable non metastatic NSCLC.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14998841.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


6. Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R, Head and Neck Cancer Disease Site Group: Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol; 2010 Jun;17(3):37-48
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
  • QUESTION: What are the benefits associated with the use of anti-epidermal growth factor receptor (anti-EGFR) therapies in squamous cell carcinoma of the head and neck (HNSCC)?
  • Anti-EGFR therapies of interest included cetuximab, gefitinib, lapatinib, zalutumumab, erlotinib, and panitumumab.
  • PERSPECTIVES: Head-and-neck cancer includes malignant tumours arising from a variety of sites in the upper aerodigestive tract.
  • The most common histologic type is squamous cell carcinoma, and most common sites are the oral cavity, the oropharynx, the hypopharynx, and the larynx.
  • Worldwide, HNSCC is the sixth most common neoplasm, and despite advances in therapy, long-term survival in HNSCC patients is poor.
  • Primary surgery followed by chemoradiation, or primary chemoradiation, are the standard treatment options for patients with locally advanced (stages III-IVB) HNSCC; however, meta-analytic data indicate that the benefit of concurrent platinum-based chemotherapy disappears in patients over the age of 70 years.
  • Cetuximab is a monoclonal antibody approved for use in combination with radiation in the treatment of patients with untreated locally advanced HNSCC and as monotherapy for patients with recurrent or metastatic (stage IVC) HNSCC who have progressed on platinum-based therapy.
  • Given the interest in anti-EGFR agents in advanced HNSCC, the Head and Neck Cancer Disease Site Group (DSG) of Cancer Care Ontario's Program in Evidence-Based Care (PEBC) chose to systematically review the literature pertaining to this topic so as to develop evidence-based recommendations for treatment.
  • OUTCOMES: Outcomes of interest included overall and progression-free survival, quality of life, tumour response rate and duration, and the toxicity associated with the use of anti-EGFR therapies.
  • METHODOLOGY: The medline, embase, and Cochrane Library databases, the American Society of Clinical Oncology online conference proceedings, the Canadian Medical Association InfoBase, and the National Guidelines Clearinghouse were systematically searched to locate primary articles and practice guidelines.
  • The randomized controlled trials (RCTS) involved three distinct patient populations: those with locally advanced HNSCC being treated for cure, those with incurable advanced recurrent or metastatic HNSCC being treated with first-line platinum-based chemotherapy, and those with incurable advanced recurrent or metastatic HNSCC who had disease progression despite, or who were unsuitable for, first-line platinum-based chemotherapy.
  • Platinum-based chemoradiation remains the current standard of care for treatment of locally advanced HNSCC.
  • In patients with locally advanced HNSCC who are medically unsuitable for concurrent platinum based chemotherapy or who are over the age of 70 years (because concurrent chemotherapy does not appear to improve overall survival in this patient population), the addition of cetuximab to radical radiotherapy should be considered to improve overall survival, progression-free survival, and time to local recurrence.Cetuximab in combination with platinum-based combination chemotherapy is superior to chemotherapy alone in patients with recurrent or metastatic HNSCC, and is recommended to improve overall survival, progression-free survival, and response rate.The role of anti-EGFR therapies in the treatment of locally advanced HNSCC is currently under study in large randomized trials, and patients with HNSCC should continue to be offered clinical trials of novel agents aimed at improving outcomes.
  • However, five ongoing trials are investigating the effect of the addition of EGFR inhibitors concurrently with, before, or after chemoradiotherapy; those trials should provide direction about the best integration of cetuximab into standard treatment.
  • In patients with recurrent or metastatic HNSCC who experience progressive disease despite, or who are unsuitable for, first-line platinum-based chemotherapy, gefitinib at doses of 250 mg or 500 mg daily, compared with weekly methotrexate, did not increase median overall survival [hazard ratio (hr): 1.22; 96% confidence interval (ci): 0.95 to 1.57; p = 0.12 (for 250 mg daily vs. weekly methotrexate); hr: 1.12; 95% ci: 0.87 to 1.43; p = 0.39 (for 500 mg daily vs. weekly methotrexate)] or objective response rate (2.7% for 250 mg and 7.6% for 500 mg daily vs. 3.9% for weekly methotrexate, p > 0.05).
  • As compared with methotrexate, gefitinib was associated with an increased incidence of tumour hemorrhage (8.9% for 250 mg and 11.4% for 500 mg daily vs. 1.9% for weekly methotrexate).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1995 Jul;72(1):123-8 [7599040.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1757-65 [18946061.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1226-31 [9508211.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1796-807 [10974628.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1523-32 [11410486.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 14):18-30 [12422310.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):555-9 [12566295.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):246-54 [12909240.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 6:vi20-vi24 [15987992.001]
  • [Cites] Expert Opin Biol Ther. 2005 Aug;5(8):1085-93 [16050785.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8646-54 [16314626.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2659-65 [16763280.001]
  • [Cites] Cancer Biol Ther. 2006 Apr;5(4):340-2 [16808060.001]
  • [Cites] J Dent Res. 2007 Feb;86(2):104-14 [17251508.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2191-7 [17538164.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S112-4 [17848275.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):407-20 [18334711.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1116-27 [18784101.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]
  • (PMID = 20567625.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2880902
  • [Keywords] NOTNLM ; Head-and-neck cancer / egfr inhibitors / epidermal growth factor receptor / overall survival / progression-free survival / tumour response rate
  •  go-up   go-down


7. Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY: CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope; 2009 Aug;119(8):1518-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD44 variant isoforms in head and neck squamous cell carcinoma progression.
  • OBJECTIVES/HYPOTHESIS: The CD44 family of receptors includes multiple variant isoforms, several of which have been linked to malignant properties including migration, invasion, and metastasis.
  • The objective of this study was to investigate the role of the CD44 v3, v6, and v10 variant isoforms in head and neck squamous cell carcinoma (HNSCC) tumor progression behaviors.
  • STUDY DESIGN: Laboratory study involving cell cultures and clinical tissue specimens.
  • Immunohistochemical analysis was performed on clinical tissue specimens obtained from a series of 82 HNSCC patients.
  • The expression of standard CD44s and the CD44 v3, v6, and v10 variants in primary tumor specimens (n = 82) and metastatic cervical lymph nodes (n = 24) were analyzed with respect to various clinicopathologic variables.
  • Compared with primary tumors, a greater proportion of metastatic lymph nodes demonstrated strong expression of CD44 v3 (lymph node 14/24 vs. primary tumor 38/82), CD44 v6 (lymph node 18/24 vs. primary tumor 26/82), and CD44 v10 (lymph node 14/24 vs. primary tumor 16/82), while expression of standard CD44 was not significantly different in metastatic lymph nodes and primary tumors (lymph node 10/24 vs. primary tumor 60/82).
  • Furthermore, expression of certain CD44 variants may be important molecular markers for HNSCC progression and should be investigated as potential therapeutic targets for therapy.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2000 Mar;85(4):514-8 [10691836.001]
  • [Cites] Semin Cancer Biol. 2008 Aug;18(4):251-9 [18450475.001]
  • [Cites] Jpn J Cancer Res. 2000 Apr;91(4):410-5 [10804289.001]
  • [Cites] Hum Pathol. 2000 Sep;31(9):1088-95 [11014576.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Oct;126(10):1217-23 [11031408.001]
  • [Cites] Tumour Biol. 2001 Jan-Feb;22(1):45-53 [11054026.001]
  • [Cites] J Surg Oncol. 2001 Feb;76(2):115-20 [11223837.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Apr;124(4):426-32 [11283501.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5275-83 [11431370.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):628-35 [11764382.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4067-72 [11751503.001]
  • [Cites] J Biol Chem. 2001 Dec 28;276(52):48679-92 [11606575.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4589-92 [11717317.001]
  • [Cites] J Lab Clin Med. 2002 Jan;139(1):59-65 [11873246.001]
  • [Cites] Arthritis Rheum. 2002 Aug;46(8):2059-64 [12209509.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):745-7 [12213700.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):25285-8 [12738783.001]
  • [Cites] Auris Nasus Larynx. 2004 Mar;31(1):35-41 [15041052.001]
  • [Cites] Exp Cell Res. 2004 Apr 15;295(1):102-18 [15051494.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):26991-7007 [15090545.001]
  • [Cites] Exp Mol Pathol. 2004 Aug;77(1):18-25 [15215046.001]
  • [Cites] Front Biosci. 1998 Jul 1;3:d637-49 [9634539.001]
  • [Cites] Cell. 1991 Apr 5;65(1):13-24 [1707342.001]
  • [Cites] J Exp Med. 1993 Feb 1;177(2):443-55 [8426113.001]
  • [Cites] J Cell Physiol. 1995 Jan;162(1):127-33 [7529235.001]
  • [Cites] J Pathol. 1996 May;179(1):66-73 [8691348.001]
  • [Cites] J Cell Physiol. 1997 May;171(2):152-60 [9130462.001]
  • [Cites] J Cell Physiol. 1998 Jul;176(1):206-15 [9618160.001]
  • [Cites] Front Biosci. 1999 Jan 1;4:A1-8 [9872731.001]
  • [Cites] Cell Motil Cytoskeleton. 1999;43(4):269-87 [10423269.001]
  • [Cites] Int J Cancer. 1999 Sep 9;82(6):837-45 [10446451.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Jan;132(1):19-24 [16415424.001]
  • [Cites] J Biol Chem. 2006 May 19;281(20):14026-40 [16565089.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1356-65 [16557236.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Jul;132(7):771-8 [16847188.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1163-8 [16855392.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Mar;133(3):281-8 [17372087.001]
  • [Cites] Head Neck. 2007 Jun;29(6):550-8 [17252589.001]
  • [Cites] Mol Cancer Res. 2007 Jun;5(6):553-67 [17579117.001]
  • [Cites] J Biol Chem. 2007 Jul 6;282(27):19426-41 [17493932.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17635-51 [18441325.001]
  • [Cites] J Cell Physiol. 2000 May;183(2):182-95 [10737894.001]
  • (PMID = 19507218.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA066163-14; United States / NCI NIH HHS / CA / R01 CA078633-10; United States / NIAMS NIH HHS / AR / P01 AR039448-190007; United States / NCI NIH HHS / CA / CA078633-10; United States / NCI NIH HHS / CA / R01 CA066163-14; United States / NCI NIH HHS / CA / R01 CA66163; United States / NIAMS NIH HHS / AR / P01 AR039448; United States / NCI NIH HHS / CA / R01 CA078633; United States / NIAMS NIH HHS / AR / AR039448-190007; United States / NIAMS NIH HHS / AR / P01 AR39448; United States / NCI NIH HHS / CA / R01 CA066163
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / Protein Isoforms
  • [Other-IDs] NLM/ NIHMS113866; NLM/ PMC2718060
  •  go-up   go-down


8. Agrawal R: Synchronous dual malignancy: successfully treated cases. J Cancer Res Ther; 2007 Jul-Sep;3(3):153-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The occurrence of a second malignancy in a patient with a known malignant tumour is not uncommon.
  • Synchronous primary malignancies are still unusual We are presenting two cases treated successfully at our centre.
  • Histopathology of cervix showed squamous cell carcinoma (large cell non keratinizing) and clinical stage was IIIB.
  • Patient was treated with external beam radiotherapy for carcinoma cervix and breast simultaneously and chemotherapy as required.
  • HPE brain tissue showed astrocytoma grade II and HPE parotid tumour showed low grade muco-epidermoid carcinoma.
  • Thus it was concluded that patients responded well to treatment.
  • Treatment strategies in case of synchronous double malignancy depend on treating the malignancy that is more advanced first or sometimes both could be treated simultaneously.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy. Carcinoma, Squamous Cell / therapy. Neoplasms, Multiple Primary / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Treatment Outcome


9. Pentheroudakis G, Briasoulis E, Kalofonos HP, Fountzilas G, Economopoulos T, Samelis G, Koutras A, Karina M, Xiros N, Samantas E, Bamias A, Pavlidis N, Hellenic Cooperative Oncology Group: Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study. Acta Oncol; 2008;47(6):1148-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.
  • We sought to optimise the regimen as a suitable outpatient palliative treatment for cancer of unknown primary (CUP).
  • PATIENTS AND METHODS: Eligible CUP patients with adenocarcinoma or poorly differentiated carcinoma, performance status of 0-2, adequate organ function and assessable disease were treated with docetaxel 75 mg/m(2) and carboplatin at an area under the concentration time-curve (AUC) of 5, both as 30-minute intravenous infusions, every three weeks.
  • Patients with isolated axillary adenopathy, squamous cell cervical or inguinal adenopathy and PSA or germ-cell serum tumour markers were excluded.
  • A median of 6 cycles of chemotherapy were administered, with relative dose intensities of both drugs >90%.
  • Granulocyte-colony stimulating factor support was used in a third of treatment cycles.
  • Median time to progression (TTP) and overall survival (OS) were 5.5 and 16.2 months respectively.
  • CONCLUSIONS: One-hour docetaxel/carboplatin is a convenient, safe and effective outpatient palliative treatment for CUP patients, providing meaningful survival prolongation only in favourable-risk patients.
  • Insights in the molecular biology of CUP are needed for the development of targeted therapeutic manipulations of malignant resistance and progression.
  • [MeSH-major] Adenocarcinoma / drug therapy. Ambulatory Care. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Neoplasms, Unknown Primary / drug therapy. Outpatients. Palliative Care / methods
  • [MeSH-minor] Adult. Aged. Area Under Curve. Carboplatin / administration & dosage. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Female. Greece. Humans. Infusions, Intravenous. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Predictive Value of Tests. Prognosis. Risk Factors. Taxoids / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607872.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


10. Kovács AF, Eberlein K, Smolarz A, Weidauer S, Rohde S: [Organ-preserving treatment in inoperable patients with primary oral and oropharyngeal carcinoma: chances and limitations]. Mund Kiefer Gesichtschir; 2006 May;10(3):168-77
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Organ-preserving treatment in inoperable patients with primary oral and oropharyngeal carcinoma: chances and limitations].
  • [Transliterated title] Organerhaltende Therapie bei inoperablen Patienten mit primären Mundhöhlen- und Oropharynxkarzinomen: Möglichkeiten und Grenzen.
  • INTRODUCTION: The aim of this study was to demonstrate the chances of nonoperative therapy in those patients from an unselected population suffering from primary previously untreated squamous cell carcinomas of the oral cavity and the oropharynx who did not seem to be operable.
  • Of the inoperable patients, 95%suffered from far-advanced stage IV disease, 8% had distant metastases, 14% had synchronous malignancies, 9% were aged over 85 years combined with advanced malignant disease, and nearly 50% were limited in their activity or were even bedridden.
  • Depending on fitness and tumor extent, three therapy regimens were used: intra-arterial (i.a.) high-dose chemotherapy with systemic antagonization for palliation, induction with this i.a. high-dose chemotherapy followed by additional radiotherapy, and induction with the i.a. high-dose chemotherapy followed by additional radiochemotherapy.
  • RESULTS: Thirty-two patients were treated with i.a. chemotherapy alone for palliation with few acute side effects.
  • The response rate was 34%, and a further growth of the tumour could be inhibited in 49%.
  • Of the patients, 22% had to cut short additional radiotherapy and 47% had to discontinue concomitant chemotherapy.
  • Viewed with caution, sex (male), performance state (ECOG) <3, and positive response to i.a. chemotherapy could be regarded as predictors for therapeutic success.
  • The combination of i.a. chemotherapy and radiochemotherapy seemed to be most successful.
  • Conversely, the therapies offered could not achieve a substantial improvement of survival in 80% of patients classified as inoperable; the most successful therapy combination could be offered to merely 23% of patients as classified inoperable due to reduced general condition.
  • The i.a. high-dose chemotherapy has to be regarded as a well tolerated and effective palliation.
  • This descriptive analysis must be followed by specific studies to establish clinical treatment recommendations.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Cisplatin / administration & dosage. Mouth Neoplasms / drug therapy. Oropharyngeal Neoplasms / drug therapy. Palliative Care / methods. Taxoids / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retreatment. Survival Rate

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] J Craniomaxillofac Surg. 2006 Mar;34(2):74-84 [16427296.001]
  • [Cites] J Craniomaxillofac Surg. 2002 Apr;30(2):112-20 [12069515.001]
  • [Cites] Head Neck. 2000 Oct;22(7):687-93 [11002324.001]
  • [Cites] Head Neck. 2005 Oct;27(10):843-50 [16161069.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1318-24 [9552032.001]
  • [Cites] Otolaryngol Head Neck Surg. 2005 Apr;132(4):570-6 [15806047.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jan;34(1):27-32 [15617963.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Feb;63(2):185-90 [15690286.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):161-6 [14697434.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • (PMID = 16604330.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Zhou XH: Primary squamous cell carcinoma of the thyroid. Eur J Surg Oncol; 2002 Feb;28(1):42-5
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary squamous cell carcinoma of the thyroid.
  • AIMS: To investigate the clinical features and treatment protocol of squamous cell carcinoma of the thyroid (SCCT).
  • RESULTS: Two patients who underwent surgical excision plus radiotherapy died of local tumour recurrence, 6 and 13 months, respectively, post-operatively.
  • The fourth patient who had radical surgery coupled with radiotherapy and chemotherapy was disease-free at 26-month follow-up.
  • CONCLUSION: SCCT is a very rare but highly malignant carcinoma.
  • Radiotherapy and chemotherapy are secondary applicable methods for the patients with certain condition.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Thyroid Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Middle Aged. Survival Rate. Thyroidectomy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Harcourt Publishers Limited.
  • (PMID = 11869012.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Uğraş S, Akpolat N, Er M, Yalçýnkaya I, Karaayvaz M: Primary composite tumour with bipartite differentiation of the esophagus. Acta Chir Belg; 2000 Feb;100(1):39-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary composite tumour with bipartite differentiation of the esophagus.
  • Primary small cell carcinoma of the esophagus is a rare tumour.
  • A primary composite tumour of the esophagus is even rarer and only four cases had been reported in the literature up to August 1998.
  • The definitive histogenesis of this tumour remains controversial in spite of the additional information provided by electron microscopy and immunohistochemistry.
  • In the presented case, histologically, the tumour tissue was composed of two malignant components: approximately 50% of a moderately differentiated squamous cell carcinoma, and approximately 50% of a small cell carcinoma.
  • A lot of morphological transition zones were observed between the squamous cell carcinoma components and the small cell carcinoma components in some areas in the squamous cell carcinoma component.
  • Histochemically and immunohistochemically, the small cell carcinoma cells demonstrated argyrophil granules, and Cytokeratin and Chromogranin A reactivity, but the squamous cell carcinoma cells demonstrated only Cytokeratin reactivity.
  • Negative reactivity for argentaffin granules, neuron-specific enolase and S-100 were observed in both the small cell carcinoma and the squamous cell carcinoma components.
  • Histological, histochemical and immunohistochemical findings suggest that a primary composite tumour of the esophagus may be derived from a totipotent primitive cell in the basal region of the squamous mucosa of the esophagus.
  • The patient received chemotherapy preoperatively but died one month after the initial diagnosis.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Biopsy, Needle. Combined Modality Therapy. Esophagectomy. Esophagoscopy. Fatal Outcome. Humans. Immunohistochemistry. Male

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10776528.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] BELGIUM
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 25
  •  go-up   go-down


13. Johann S, Mueller MD: [Follow-up after malignant tumours of the uterus (cancer of the uterine corpus / cervical cancer)]. Ther Umsch; 2008 Jun;65(6):341-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Follow-up after malignant tumours of the uterus (cancer of the uterine corpus / cervical cancer)].
  • Malignant uterine tumours can affect the corpus or the cervix.
  • Cervical cancer presents an own entitity, regarding both histology and therapeutic options.
  • Histologically, the endometrial cancer can be subdivided in two groups: type I is hormonal sensitive and well differentiated, type II represents an undifferenciated aggressive tumour with poor prognosis.
  • First choice in therapy is stage related surgery.
  • Cervical cancer is mainly a squamous cell carcinoma and oncogenic Human Papilloma Virus (HPV) associated.
  • Surgery is only indicated up to stage IIA, advanced stages should be treated by radio-chemotherapy.
  • Intention is the detection of the curable local relapse.
  • [MeSH-major] Aftercare / methods. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Second Primary / diagnosis. Postoperative Complications / diagnosis. Uterine Cervical Neoplasms / surgery. Uterine Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Evidence-Based Medicine. Female. Humans. Neoplasm Staging. Positron-Emission Tomography. Prognosis. Tomography, X-Ray Computed


14. Völter C, Baier G, Hoppe F, Schwager K, Helms J: [Diagnosis, treatment and results of malignant skull base tumours]. Laryngorhinootologie; 2001 Sep;80(9):512-6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis, treatment and results of malignant skull base tumours].
  • [Transliterated title] Diagnostik, Therapie und Ergebnisse in der Behandlung maligner Schädelbasistumoren1.
  • BACKGROUND: Malignant tumours of the cranial base are rare and present usually in advanced tumour stage due to the lack of early clinical symptoms.
  • PATIENTS AND METHODS: Sixty patients with malignant tumours infiltrating the skull base were treated at the Department of Otorhinolaryngology Head and Neck Surgery, University of Würzburg between 1987 and 1999.
  • Seven tumours were malignant brain tumours infiltrating the bony structures of the skull base or originated from the cranial base itself.
  • The histological diagnosis was confirmed in 53 patients preoperatively and in seven patients during tumour resection.
  • Squamous cell carcinoma (n = 24), adenocarcinoma (n = 10) and sarcoma (n = 7) were the most common histologies found.
  • RESULTS: A radical en bloc resection of the tumour was only possible in 26 out of 60 cases.
  • A surgical tumour reduction with postoperative radiation therapy was performed in seven patients as a palliative approach.
  • Eight patients underwent a combined radio- and chemotherapy according to the histological diagnosis.
  • Primary radiotherapy was the treatment of choice in eleven patients, where the tumours were located in the central area of the cranial base.
  • Palliative radiotherapy or solely medical pain control were applied to eight patients who presented either with distant metastases or an advanced tumour growth.
  • The mean postoperative survival following radical surgery was 48 months and after primary radiotherapy 27 months.
  • DISCUSSION: A statistical analysis of the results is not applicable due to the great variety of the disease concerning the histological diagnosis, the tumour size and the location as well as the small number of patients.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Squamous Cell. Esthesioneuroblastoma, Olfactory. Sarcoma. Skull Base Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Palliative Care. Postoperative Complications. Survival Analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11555782.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


15. Charabi S, Balle V, Charabi B, Nielsen P, Thomsen J: Surgical outcome in malignant parotid tumours. Acta Otolaryngol Suppl; 2000;543:251-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcome in malignant parotid tumours.
  • Of 494 parotid gland tumours treated in Copenhagen county (population 600,000 inhabitants) in the period 1986-95, 50 patients (34 males, 16 females) had tumours that were proven to be malignant, making an incidence of 0.62/100,000/year.
  • The material included 41 primary parotid gland tumours, histologically the tumours were verified as mucoepidermoid carcinoma (n = 13), adenocarcinoma (n = 9), squamous cell carcinoma (n = 6), carcinoma ex pleomorph adenoma (n = 3), acinic cell carcinoma (n = 3), adenoid cystic carcinoma (n = 3) and other histological diagnoses (n = 4).
  • Primary malignant lymphoma of the parotid gland was diagnosed in six tumours and the last three tumours were metastatic carcinoma.
  • Four therapeutic modalities were applied: surgery only, surgery + radiation, surgery + chemotherapy, and surgery + chemotherapy + radiation.
  • Surgical radicality was achieved in 76% and radicality was unrelated to tumour histology.
  • No significant difference was observed in 5-year crude survival or in the post-operative facial nerve function between the radically operated patients (n = 38) and patients with residual tumour (p = 0.27, Log-rank test), (p = 0.48, chi 2 test).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Catchment Area (Health). Combined Modality Therapy. Denmark / epidemiology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10909035.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] NORWAY
  •  go-up   go-down


16. Siveke JT, Sen Gupta R, Rieckhoff KU, Braumann D, Goldmann T: [Progressive paralysis caused by radiation-induced cervical malignant peripheral nerve sheath tumor]. HNO; 2003 Oct;51(10):825-8
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Progressive paralysis caused by radiation-induced cervical malignant peripheral nerve sheath tumor].
  • Magnetic resonance tomography displayed an advanced tumour arising from the right paravertebral soft tissue.
  • Histological examination revealed a malignant peripheral nerve sheath tumor (MPNST).
  • Thirteen years before admission, the patient had a right-sided tumor-tonsillectomy of a squamous cell carcinoma and local radiation of a cystic squamous cell carcinoma in the ipsilateral cervical soft tissue.
  • CLINICAL COURSE AND THERAPY: In the following course, progressive neurological symptoms occurred including beginning paraplegia, right phrenic paralysis and a severe concomitant pain syndrome.
  • Due to the location and advanced tumor state, surgical treatment was not performed and palliative chemotherapy remained ineffective.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / diagnosis. Neoplasms, Multiple Primary / radiotherapy. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Second Primary / diagnosis. Nerve Sheath Neoplasms / diagnosis. Paraparesis / etiology. Radioisotope Teletherapy / adverse effects. Tonsillar Neoplasms / radiotherapy
  • [MeSH-minor] Arm / innervation. Combined Modality Therapy. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radiotherapy, Adjuvant. Respiratory Paralysis / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - paralysis.
  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1981 May 15;47(10):2503-9 [6791802.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1247-53 [8435801.001]
  • [Cites] Cancer. 1983 Mar 15;51(6):1028-33 [6821867.001]
  • [Cites] Eur J Cancer. 1995;31A(1):31-4 [7695975.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):951-61 [10571202.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):351-60 [9788415.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • (PMID = 14523537.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Altumbabić H, Salkić A, Ramas A, Burgić M, Kasumović M, Brkić F: Pattern of head and neck malignant tumours in a Tuzla ENT clinic--a five year experience. Bosn J Basic Med Sci; 2008 Nov;8(4):377-80
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of head and neck malignant tumours in a Tuzla ENT clinic--a five year experience.
  • One overriding factor in deciding on treatment policy is the tendency for head and neck malignancy to be limited to the primary site and regional lymph nodes with surgery and chemotherapy and radiotherapy.
  • The histopathological tumour types found in this work were mostly squamous cell carcinoma (72,09%), papillary carcinoma (12,2%), while many other minor histopathological variants accounted for 13%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19125712.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


18. Fernández Cotarelo MJ, Guerra Vales JM: [Therapeutic management of cancer of unknown primary site by pathological types]. Rev Clin Esp; 2009 Oct;209(9):439-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic management of cancer of unknown primary site by pathological types].
  • The term cancer of unknown primary site includes metastatic tumours with different histology and behaviour.
  • Although most of them have a poor short-term prognosis, some patients can benefit from a treatment and will achieve a longer survival.
  • The treatable cases are: metastases of squamous carcinoma in cervical or inguinal adenopathies, metastases of adenocarcinoma in axilar adenopathies in women, malignant ascites due to adenocarcinoma in women, osteoblastic bone metastases in men with elevated serum prostatic specific antigen levels, poorly differentiated tumours with features of a germinal extragonadal tumour, poorly differentiated neuroendocrine carcinomas and patients with a single metastasis.
  • Chemotherapy must be considered in the rest of patients, although the optimum regimen is not well established yet.
  • [MeSH-major] Neoplasms, Unknown Primary / pathology. Neoplasms, Unknown Primary / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Sociedad Española de Calidad Asistencial. Published by Elsevier España, S.L. All rights reserved.
  • (PMID = 19852914.001).
  • [ISSN] 0014-2565
  • [Journal-full-title] Revista clínica española
  • [ISO-abbreviation] Rev Clin Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


19. Parmar DN, Rose GE: Management of lacrimal sac tumours. Eye (Lond); 2003 Jul;17(5):599-606
MedlinePlus Health Information. consumer health - Tears.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To report a series of 15 primary lacrimal sac tumours and present an algorithm in managing this rare condition.
  • METHODS: A retrospective review of the clinical, radiological, and pathological records of 15 patients with primary lacrimal sac tumours.
  • Main outcome measures Histologic evaluation and clinical follow-up, including tumour clearance and recurrence, were assessed.
  • The commonest tumour was non-Hodgkins B-cell lymphoma (five cases), followed by two cases each of squamous cell carcinoma and transitional cell carcinoma, one case of benign transitional papilloma, haemangiopericytoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, mixed (squamous/transitional) carcinoma, and a highly malignant undifferentiated tumour.
  • Treatment modalities included surgery, radiotherapy and chemotherapy and, with a median follow-up of 30 months (range 2 months to 17 years), two patients had died from metastatic disease but nine patients remained without evidence of recurrent tumour.
  • CONCLUSIONS: Primary lacrimal sac tumours are extremely rare, require long-term follow-up for recurrence and metastasis, and can be fatal.
  • [MeSH-major] Eye Neoplasms / therapy. Lacrimal Apparatus Diseases / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Fatal Outcome. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12855966.001).
  • [ISSN] 0950-222X
  • [Journal-full-title] Eye (London, England)
  • [ISO-abbreviation] Eye (Lond)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Scarisbrick JJ, Child F, Spittle M, Calonje E, Russell-Jones R: Systemic Hodgkin's lymphoma in a patient with Sézary syndrome. Br J Dermatol; 2000 Apr;142(4):771-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a 71-year-old male with Sézary syndrome diagnosed in 1996 who subsequently developed systemic Hodgkin's lymphoma.
  • His only past treatment was bath psoralen plus ultraviolet A.
  • He has since been treated with multiagent chemotherapy (ChlVPP/PABLOE) which induced a remission in his Hodgkin's disease.
  • He has also developed a squamous cell carcinoma on the upper lip.
  • Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by a malignant proliferation of CD4-positive cells in the skin and peripheral circulation.
  • Immunosuppression is known to be associated with an increased rate of malignancies and this may account for the occurrence of Hodgkin's disease and squamous cell carcinoma in this patient with Sézary syndrome.
  • [MeSH-major] Carcinoma, Squamous Cell. Hodgkin Disease. Lip Neoplasms. Neoplasms, Multiple Primary. Sezary Syndrome. Skin Neoplasms
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Immune Tolerance / immunology. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Sezary syndrome.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10792230.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


21. Apalla Z, Sotiriou E, Chovarda E, Lefaki I, Devliotou-Panagiotidou D, Ioannides D: Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study. Br J Dermatol; 2010 Jan;162(1):171-5
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study.
  • Background Patients with a previous medical history of nonmelanoma skin cancers (NMSCs) often develop multiple or recurrent malignant lesions around the site of the primary tumour.
  • This finding led to the field cancerization theory, which suggests that the entire epithelial surface of the regional skin has an increased risk for the development of malignant lesions.
  • Objectives We sought to investigate whether field-photodynamic therapy (PDT) of extreme photodamaged skin would prevent new NMSCs, in comparison with a control area receiving placebo-PDT, in patients with clinical and histological signs of field cancerization.
  • Methods Forty-five patients, previously diagnosed as having NMSCs of the face or scalp, with actinic keratoses symmetrically distributed over the same regions, were randomized for field treatment with 20% aminolaevulinic acid (ALA)-PDT on one side and placebo-PDT on the other.
  • Results A significant delay in the mean time of appearance and a reduction in the total number of new lesions were observed in the field-PDT protocol, when compared with the control.
  • Conclusions The results obtained showed that field therapy with ALA-PDT confers a significant preventive potential against the formation of new NMSCs in patients with field changes.
  • [MeSH-major] Facial Neoplasms / prevention & control. Head and Neck Neoplasms / drug therapy. Neoplasms, Second Primary / prevention & control. Photochemotherapy. Scalp. Skin Neoplasms / prevention & control
  • [MeSH-minor] Aged. Aged, 80 and over. Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Female. Humans. Keratosis, Actinic / drug therapy. Male. Middle Aged. Photosensitizing Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863513.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down






Advertisement